(Total Views: 461)
Posted On: 02/20/2021 12:17:10 AM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
CCR5delta32 genotyping in the Yo/Patterson project.
Yesterday Patterson announced first round of results.
100 patients total genotyped.
20% of mild/moderate covid patients are heterozygous for delta32.
25% of covid long haulers are heterozygous for delta32.
4% of covid severe/critical are heterozygous for delta32.
No homozygotes so far.
100 patients is nowhere enough for statistical significance, but as they say its a trend so far.
Patterson/Yo seem to have a lot of momentum so perhaps not too long before they report on 1000 genotyped patient results.
20% seems high as USA general population is more like 10%, I think.
Yesterday Patterson announced first round of results.
100 patients total genotyped.
20% of mild/moderate covid patients are heterozygous for delta32.
25% of covid long haulers are heterozygous for delta32.
4% of covid severe/critical are heterozygous for delta32.
No homozygotes so far.
100 patients is nowhere enough for statistical significance, but as they say its a trend so far.
Patterson/Yo seem to have a lot of momentum so perhaps not too long before they report on 1000 genotyped patient results.
20% seems high as USA general population is more like 10%, I think.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)